NP-DNA-NDDS

Multifunctional theranostic nanoparticles using pH-responsive DNA-nanoparticle conjugate for effective cancer therapy

Coordinatore	UNIVERSITY OF LEEDS    more  Organization address address: WOODHOUSE LANE city: LEEDS postcode: LS2 9JT contact info Titolo: Mr. Nome: Martin Cognome: Hamilton Email: send email Telefono: +44 113 343 4090 Fax: +44 113 343 0949
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	309˙235 €
EC contributo	309˙235 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IIF
Funding Scheme	MC-IIF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-10-01   -   2015-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF LEEDS  Organization address address: WOODHOUSE LANE city: LEEDS postcode: LS2 9JT contact info Titolo: Mr. Nome: Martin Cognome: Hamilton Email: send email Telefono: +44 113 343 4090 Fax: +44 113 343 0949	UK (LEEDS)	coordinator	309˙235.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths in 2008. Although conventional cancer chemotherapy can provide profound benefits, seriously adverse side-effects still cannot be avoided, due to lack of specific targeting nature of current treatments. Nanomedicine can reduce such side-effects by exploiting characteristic properties of tumors for targeted delivery and therapy. Despite extensive research, most nanomedicines developed so far have relied on passive targeting using a single therapeutic modality, which are inefficient for treatment of challenging conditions such as multi-drug resistance.

Recently we developed a pH-responsive-DNA-GNP conjugate based nanocarrier that numerous features required for an ideal drug nanocarrier, e.g. uniform small nanoscale size, resisting non-specific adsorption, non-toxic, biocompatible, water-soluble, stable, and having high drug loading and controlled release capacities. It can offer efficient and pH-triggered drug release suitable for effective cancer chemotherapy at the cellular level using doxorubicin, a widely used chemotherapy drug.

Herein we will extend it into a more effective, multifunctional nanomedicine that can offer simultaneous biomodal chemotherapies with hyperthermia and MRI imaging capacities. First, we will prepare, characterize, and evaluate their drug loading & release profiles in buffer; then we will study and quantify their cell- & cell-specific- uptake and drug delivery efficiency, and then evaluate their toxicity, cytotoxicity & cell-specific cytotoxicity with cancer cells (incoming phase), and finally evaluate their synergistic therapeutic efficacy at cellular and preclinical level (re-integration phase). This project will greatly benefit both the fundamental research in nanomedicine and the healthcare/pharmaceutical indurstries in Europe.'